Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 22 Results

Title
Intervention Indication Therapeutic Area Year Actions
Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs Risankizumab (BI 655066; Skyrizi; ABBV 066) Psoriatic arthritis Dermatology , Rheumatology 2017 View  |  Download
Sarilumab for treating Polyarticular-course Juvenile idiopathic arthritis in children and adolescents Sarilumab Juvenile idiopathic arthritis Rheumatology 2023 View  |  Download
Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years Secukinumab (Cosentyx; AIN457) Enthesitis-related arthritis , Juvenile psoriatic arthritis Rheumatology 2019 View  |  Download
Secukinumab for Non-Radiographic Axial Spondyloarthritis – second or subsequent line Secukinumab (Cosentyx; AIN457) Spondyloarthritis Musculoskeletal System , Rheumatology 2018 View  |  Download
Subcutaneous Tocilizumab (RoACTEMRA) With or Without Methotrexate for the Treatment of Inadequate Responders in Systemic Juvenile Idiopathic Arthritis Methotrexate (MTX; Otrexup; Vibex MTX; MQX-5902; methotrexate disodium; methotrexate sodium) , Tocilizumab (Actemra; R1569; RoActemra) Juvenile idiopathic arthritis Rheumatology 2017 View  |  Download
Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain Tanezumab (PF-04383119; RN624) Back pain , Osteoarthritic pain Musculoskeletal System , Pain Relief , Rheumatology 2019 View  |  Download
Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure Tocilizumab (Actemra; R1569; RoActemra) Rheumatoid arthritis Rheumatology 2017 View  |  Download
Tocilizumab biosimilar for treating moderate to severe active rheumatoid arthritis Tocilizumab biosimilar (Avtozma) Rheumatoid arthritis Rheumatology 2023 View  |  Download
Tofacitinib for polyarticular juvenile idiopathic arthritis Tofacitinib citrate (Xeljanz; CP-690550) Juvenile idiopathic arthritis Rheumatology 2019 View  |  Download
Upadacitinib for active psoriatic arthritis with inadequate response to biological or non-biological DMARDs Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Psoriatic arthritis Dermatology , Rheumatology 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications